PVR and neuroendocrine neoplasm: Other immune checkpoint ligand molecules, such as CTLA-4, galectin-9 and CD155, have been investigated in some neuroendocrine tumors and their expression has been associated with better prognosis and response to immune checkpoint inhibitors [31,32,33].